<scp>PTPN11</scp> mutations in canine and human disseminated histiocytic sarcoma
Benoît Hédan, Mélanie Rault, Jérôme Abadie, Ronan Ulvé, Nadine Botherel, Patrick Devauchelle, Christiane Copie‐Bergman, Édouard Cadieu, Marie Parrens, Julia Alten, Emmanuelle L. Zalcman, Gunnar Cario, Gandhi Damaj, Karima Mokhtari, François Le Loarer, Aurore Coulomb L’Herminé, Thomas Derrien, Christophe Hitte, Laura Bachelot, Matthew Breen, David Gilot, Jean‐Yves Blay, Jean Donadieu, Catherine André
Abstract
In humans, histiocytic sarcoma (HS) is an aggressive cancer involving histiocytes. Its rarity and heterogeneity explain that treatment remains a challenge. Sharing high clinical and histopathological similarities with human HS, the canine HS is conversely frequent in specific breeds and thus constitutes a unique spontaneous model for human HS to decipher the genetic bases and to explore therapeutic options. We identified sequence alterations in the MAPK pathway in at least 63.9% (71/111) of HS cases with mutually exclusive BRAF (0.9%; 1/111), KRAS (7.2%; 8/111) and PTPN11 (56.75%; 63/111) mutations concentrated at hotspots common to human cancers. Recurrent PTPN11 mutations are associated to visceral disseminated HS subtype in dogs, the most aggressive clinical presentation. We then identified PTPN11 mutations in 3/19 (15.7%) human HS patients. Thus, we propose PTPN11 mutations as key events for a specific subset of human and canine HS: the visceral disseminated form. Finally, by testing drugs targeting the MAPK pathway in eight canine HS cell lines, we identified a better anti-proliferation activity of MEK inhibitors than PTPN11 inhibitors in canine HS neoplastic cells. In combination, these results illustrate the relevance of naturally affected dogs in deciphering genetic mechanisms and selecting efficient targeted therapies for such rare and aggressive cancers in humans.